Yin Wang

Personalized Drug Research And Therapy Key Laboratory Of Sichuan Province
Chengdu, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS).

Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS).

Journal: Frontiers in cardiovascular medicine

Published: September 25, 2025

RNF220 enhances USP22 to promote cell growth, metastasis and stemness in hepatocellular carcinoma by activating the Akt pathway.

RNF220 enhances USP22 to promote cell growth, metastasis and stemness in hepatocellular carcinoma by activating the Akt pathway.

Journal: Cell cycle (Georgetown, Tex.)

Published: September 12, 2025

Comparative efficacy and safety of second-line therapies for patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis of randomized controlled trials.

Comparative efficacy and safety of second-line therapies for patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis of randomized controlled trials.

Journal: Frontiers in pharmacology

Published: September 03, 2025

A study on a real-world data-based VTE risk prediction model for lymphoma patients.

A study on a real-world data-based VTE risk prediction model for lymphoma patients.

Journal: Frontiers in pharmacology

Published: August 23, 2025

Development of a venous thromboembolism risk prediction model for patients with primary membranous nephropathy based on machine learning.

Development of a venous thromboembolism risk prediction model for patients with primary membranous nephropathy based on machine learning.

Journal: Frontiers in pharmacology

Published: August 21, 2025

Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system.

Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system.

Journal: PloS one

Published: August 10, 2025

Revolutionizing anticoagulation: DOAC versus VKA in atrial fibrillation with early post-bioprosthetic valves replacement or valves repair.

Revolutionizing anticoagulation: DOAC versus VKA in atrial fibrillation with early post-bioprosthetic valves replacement or valves repair.

Journal: International journal of surgery (London, England)

Published: July 06, 2025

Efficacy and safety of oral anticoagulants in the treatment of chronic kidney disease with atrial fibrillation or venous thromboembolism: a systematic review and meta-analysis.

Efficacy and safety of oral anticoagulants in the treatment of chronic kidney disease with atrial fibrillation or venous thromboembolism: a systematic review and meta-analysis.

Journal: Frontiers in pharmacology

Published: April 21, 2025

COVID-19: a vascular nightmare unfolding.

COVID-19: a vascular nightmare unfolding.

Journal: Frontiers in immunology

Published: March 17, 2025

Showing 1-9 of 9

Last Updated: 09/26/2026